BPA for empaveli. Base year with four one-year option periods.
Active Awarded Last action
- Contract number
- 36E79722A0014
- Awardee
-
APL Sales I LLC UEI XXKJSCZRL266 Part of Apellis Pharmaceuticals, Inc.
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 91% complete
- IDV ceiling
- $2,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc., has been awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs National Acquisition Center for the supply of EMPAVELI (pegcetacoplan), a complement C3 inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria, a rare blood disorder affecting red blood cells. The contract, awarded March 30, 2022, carries a ceiling value of $2,000,000 with an ultimate completion date of March 29, 2027, structured on a base year plus four one-year option periods. No set-aside designation was used in the award. The contract operates as an indefinite delivery vehicle enabling the Veterans Health Administration to procure this specialized pharmaceutical product through streamlined delivery orders rather than individual solicitations, facilitating efficient supply chain management for critical pharmaceutical treatments across the VA medical system.
Under this blanket purchase agreement, the Veterans Health Administration places firm fixed-price delivery orders for EMPAVELI supplies, typically valued between $25,000 and $26,000 per order with short performance periods of one to two weeks. Delivery orders have been exclusively fulfilled through the Veterans Integrated Service Network 5, which serves western Pennsylvania and parts of West Virginia, ensuring consistent pharmaceutical availability for veteran patients requiring this complement inhibitor therapy. The contract vehicle complements APL Sales I LLC's parallel multiple-award Federal Supply Schedule contract under the Pharmaceuticals and Drugs schedule (FSS-61-IB) with a $225,000 ceiling value, providing the VA with dual procurement mechanisms for obtaining EMPAVELI and related pharmaceutical products to support comprehensive veteran healthcare services.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79722A0014?
36E79722A0014 was awarded to APL Sales I LLC by National Acquisition Center (Headquarters) on March 30, 2022.
How much is contract 36E79722A0014 worth?
36E79722A0014's own ceiling is $2,000,000.
Who can order from contract 36E79722A0014?
36E79722A0014 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79722A0014 under another contract?
Yes. 36E79722A0014 is a blanket purchase agreement under 36F79722D0039, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79722A0014 competed?
The extent of competition for 36E79722A0014 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV